Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Intravenous Iron Drugs Market Growth Potential: How Will Market Size Shift Through 2030?
The market for intravenous iron drugs has experienced substantial growth in recent years. It is anticipated to expand from $3.81 billion in 2025 to $4.22 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.8%. The historical rise in this market can be linked to the significant prevalence of iron deficiency anemia, challenges associated with oral iron absorption, structured hospital protocols for anemia management, increased adoption in dialysis centers, and the demonstrated clinical efficacy of IV iron therapies.
The intravenous iron drugs market size is expected to experience significant growth in the upcoming years. It is projected to reach $6.34 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 10.7%. The anticipated growth during this period is attributable to the rising burden of chronic diseases, an expanding population of dialysis patients, an increase in cancer-related anemia cases, the demand for rapid hemoglobin correction, and the broadening of outpatient infusion services. Key trends for the forecast period include an increasing application in the management of iron deficiency anemia, a growing adoption among patients with chronic kidney disease, a developing preference over oral iron therapies, the expansion of single-dose iron formulations, and higher utilization in oncology and gastroenterology.
Get A Free Sample Report With In-Depth Market Insights:
Intravenous Iron Drugs Market Demand Drivers Opening New Revenue Streams
The increasing occurrence of chronic kidney disease (CKD) is projected to propel the expansion of the intravenous iron drugs market moving forward. Chronic kidney disease (CKD) signifies the progressive deterioration of kidney function over time, leading to the kidneys’ diminished capacity to effectively filter waste and excess fluids from the blood. This rise in CKD cases is attributed to escalating rates of diabetes and hypertension, which contribute to kidney damage over time. Intravenous iron drugs aid chronic kidney disease patients by replenishing iron stores, rectifying anemia, and enhancing hemoglobin levels, which in turn improves oxygen transport and lessens the requirement for erythropoiesis-stimulating agents. For instance, in July 2025, according to Hamadan University of Medical Sciences, a Iran-based university, the global number of newly diagnosed chronic kidney diseases is projected to rise to 25.06 million by 2030. Hence, the increasing prevalence of chronic kidney disease (CKD) is driving the growth of the intravenous iron drugs market.
Intravenous Iron Drugs Market Segment Breakdown: Which Categories Lead On Revenue?
The intravenous iron drugs market covered in this report is segmented –
1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types
2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran
2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex
3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose
4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate
Intravenous Iron Drugs Market Trends Powering Strategic Industry Growth
Leading companies active in the intravenous iron drugs market are prioritizing the creation of novel therapies, such as intravenous (IV) iron replacement therapy, to enhance effectiveness, safety, and patient outcomes. Intravenous (IV) iron replacement therapy functions as a medical procedure that delivers iron directly into the bloodstream through an intravenous infusion. This treatment addresses iron deficiency and anemia, particularly beneficial for patients who struggle to tolerate or adequately absorb oral iron supplements. For instance, in June 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical entity specializing in advanced drug development and healthcare provisions, declared that the U.S. Food and Drug Administration (FDA) had sanctioned Injectafer (ferric carboxymaltose injection) for the management of iron deficiency in adult patients suffering from heart failure classified as New York Heart Association class II/III, with the aim of boosting exercise capacity. Injectafer is a broadly applied intravenous iron treatment, noted for its rapid replenishment of iron levels in individuals who are intolerant to or do not respond well to oral iron supplements.
Intravenous Iron Drugs Market Leading Players And Competitive Positioning
Major companies operating in the intravenous iron drugs market are Pharmacosmos A/S, American Regent Inc., Fresenius SE & Co. KGaA, Sandoz Group AG, Hikma Pharmaceuticals plc, Rockwell Medical Inc., Daiichi Sankyo Company Ltd., CSL Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Limited, Vifor Pharma Management Ltd., Galenica Ltd., Aspen Pharmacare Holdings Limited, Lupin Limited, Aurobindo Pharma Limited, Jiangsu Hengrui Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Nanjing Hicin Pharmaceutical Co. Ltd
View The Full Intravenous Iron Drugs Market Report:
Intravenous Iron Drugs Market Geographic Landscape: Which Region Leads Industry Growth?
North America was the largest region in the intravenous iron drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model